Duodenal Mucosa Responses to Endoscopic Food Challenges in Patients With Inflammatory Bowel Disease and Irritable Bowel Syndrome With Self-reported Food Intolerances: A Feasibility Study (DRFC)
Duodenal Responses to Food Challenges in Patients With Self-reported Food Intolerances: a Feasibility Study
The goal of this study is to investigate the feasibility of using intravenous fluorescein during a standard endoscopy-along with a laser to activate it and an optical filter-to identify changes in the duodenal mucosa after a controlled food challenge in individuals with IBD and IBS who experience food intolerances. The main questions it aims to answer are:
- Is this technique feasible approach to assess food intolerances in patients with IBD and IBS?
- Does patients with IBD and IBS exhibit acute tissue changes upon exposure to specific food antigens?
Researches will compare the food antigen to a placebo solution (saline solution without an antigen) to see if the reaction in the tissue is different.
Participants will:
- Answer questionnaires.
- Provide a blood and stool sample.
- Take an allergy test.
- Undergo an upper endoscopy.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This is a prospective, double-arm, randomized feasibility study. This study will recruit patients with Inflammatory Bowel Disease (IBD) in remission and patients with Irritable Bowel Syndrome (IBS), who self-report food intolerances. All participants will undergo an upper endoscopy with the administration of a food challenge solution (cow's milk protein or placebo), intravenous fluoresceine administration, biopsies and fluid collection.
Upon signing informed consent, participants will be enrolled in the study. Following enrollment, participants will be randomized in a 2:1 ratio to receive either a food challenge with a cow's milk protein solution or a placebo solution during the upper endoscopy, which will occur in visit 3.
During the first visit, participants will complete questionnaires covering demographics, medical history, gastrointestinal symptoms (using the Gastrointestinal Symptoms Rating Scale), and food intolerances. Blood samples will be collected from all participants, and IBD patients will additionally provide stool samples for fecal calprotectin measurement.
In the second visit, participants will be evaluated by an experienced allergologist, and a skin prick test will be conducted to rule out an allergy to cow's milk protein.
After completing these initial evaluations, participants will be scheduled for visit 3. In preparation for this visit, participants will be instructed to avoid consuming any products containing cow's milk for five days prior. During visit 3, an upper endoscopy will be performed. Through the endoscope's working channel, either a cow's milk protein solution or a placebo solution will be delivered to the third portion of the duodenum. Additionally, eight biopsies and a fluid sample will be collected from this area. A permeability test will also be performed using intravenous fluorescein, and the procedure will be recorded on video.
Following the third visit, a follow-up phone call will be conducted to assess any symptoms that participants may have experienced post-procedure.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: David Armstrong, MD
- Telefonnummer: 76404 905 521 2100
- E-Mail: armstro@mcmaster.ca
Studieren Sie die Kontaktsicherung
- Name: Liam Rondeau, PhD
- Telefonnummer: 76404 19055259140
- E-Mail: rondeaul@mcmaster.ca
Studienorte
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8S 4K1
- McMaster University Medical Centre
-
Hauptermittler:
- David Armstrong, MD
-
Kontakt:
- David Armstrong, MD
- Telefonnummer: 76404 905 521 2100
- E-Mail: armstro@mcmaster.ca
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Confirmed diagnosis of IBD (UC or CD) and under clinical remission for at least 3 months, OR confirmed diagnosis of IBS (any subtype) by Rome IV criteria.
- Report having one or more food intolerance.
- Able to provide informed consent.
Exclusion Criteria:
- Presence of a known food allergy.
- Presence of serum IgE positivity or a positive skin-prick test to cow's milk.
- Known allergy to fluorescein.
- Diagnosis of celiac disease.
- Positive IgA TTG antibodies.
- Pregnancy or breastfeeding.
- Presence of a contraindication for an upper endoscopy.
- History of surgery involving the upper gastrointestinal tract.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Cow's milk protein solution
A solution with 5 mL cow's milk protein fraction mixed with 50% sterile water applied onto the duodenal mucosa one time during an upper endoscopy. |
Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis
Andere Namen:
|
|
Placebo-Komparator: Placebo solution
A solution with 18 mL sterile water + 2 mL simethicone applied onto the duodenal mucosa one time during an upper endoscopy. |
Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Procedure completition
Zeitfenster: From the start of the endoscopy up to 10 minutes after the food challenge
|
Successful completion of the procedure including sample collection, administration of the food challenge, and development of a reaction in the duodenal mucosa. A positive reaction in the mucosa will be defined by the presence of intraepithelial lymphocytes >25/100 epithelial cells. |
From the start of the endoscopy up to 10 minutes after the food challenge
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Anzeichen und Symptome, Verdauungstrakt
- Darmerkrankungen
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Darmerkrankungen
- Gastroenteritis
- Darmerkrankungen, funktionell
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Lebensmittelintoleranz
- Reizdarmsyndrom
- Entzündliche Darmerkrankungen
- Untersuchungstechniken
- Handhabung von Proben
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Minimal invasive chirurgische Verfahren
- Zytologische Techniken
- Zytodiagnose
- Diagnosetechniken, chirurgisch
- Diagnosetechniken, Verdauungssystem
- Endoskopie
- Chirurgische Verfahren des Verdauungssystems
- Biopsie
- Endoskopie, Verdauungssystem
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 18305
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .